Buying guide
Versius vs Maestro in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, Versius has more verified real-world deployments (5 versus 1) than Maestro as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source.
- Maestro has the lower recorded price.
- Versius has more verified real-world deployments (5 vs 1).
| Attribute | No image on file | |
|---|---|---|
| Manufacturer | CMR Surgical | Moon Surgical |
| Form factor | surgical | surgical |
| Maturity | commercial | commercial |
| Autonomy | ◐ not independently verified | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | $750,000-$1,000,000 (analyst estimate) | $300,000-$800,000 (analyst estimate) |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 5 | 1Moon Surgical |
| Privacy practices | — | — |
| Sources on file | 25 | 9 |
Track this matchup
Get told the moment Versius or Maestro changes. Verified changes only, the second they are real. No press-release noise.
Versius
Maestro
Editorial summaries
Versius
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data.
On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.
Maestro
Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.
On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.
Common questions
How do Versius and Maestro differ?
What is the difference between Versius and Maestro?
Which is cheaper, Versius or Maestro?
Is Versius or Maestro more autonomous?
Recent coverage
- Stryker invests $400M into CMR SurgicalVersius · The Robot Report · 2026-10-15
- Stryker to Invest $400M in CMR Surgical, Gains U.S. Sales Rights and Acquisition OptionVersius · The AI Insider · 2026-10-12
- Collibra brings runtime governance to enterprise AI agentsMaestro · SiliconANGLE · 2026-09-25
- Ryuichi Sakamoto’s final memoir lays bare a maestro’s final questionsMaestro · The Japan Times · 2026-09-07
Related comparisons
- Versius vs da Vinci (and Ion)
- Versius vs Stryker Mako SmartRobotics
- Versius vs Hugo RAS
- Versius vs mBos TKA System
- Versius vs Johnson & Johnson Ottava
- Versius vs CORI
- Versius vs ROSA
- da Vinci (and Ion) vs Maestro
- Stryker Mako SmartRobotics vs Maestro
- Hugo RAS vs Maestro
- mBos TKA System vs Maestro
- Maestro vs Johnson & Johnson Ottava
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.
